1120 related articles for article (PubMed ID: 22613095)
21. Panobinostat Enhances Growth Suppressive Effects of Progestin on Endometrial Carcinoma by Increasing Progesterone Receptor and Mitogen-Inducible Gene-6.
Ando H; Miyamoto T; Kashima H; Higuchi S; Ida K; Mvunta DH; Shiozawa T
Horm Cancer; 2017 Aug; 8(4):257-267. PubMed ID: 28516379
[TBL] [Abstract][Full Text] [Related]
22. Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways.
Chen J; Li N; Liu B; Ling J; Yang W; Pang X; Li T
Life Sci; 2020 May; 248():117469. PubMed ID: 32109485
[TBL] [Abstract][Full Text] [Related]
23. Molecular Mechanism of the Cell Death Induced by the Histone Deacetylase Pan Inhibitor LBH589 (Panobinostat) in Wilms Tumor Cells.
Yan-Fang T; Zhi-Heng L; Li-Xiao X; Fang F; Jun L; Gang L; Lan C; Na-Na W; Xiao-Juan D; Li-Chao S; Wen-Li Z; Pei-Fang X; He Z; Guang-Hao S; Yan-Hong L; Yi-Ping L; Yun-Yun X; Hui-Ting Z; Yi W; Mei-Fang J; Lin L; Jian N; Shao-Yan H; Xue-Ming Z; Xing F; Jian W; Jian P
PLoS One; 2015; 10(7):e0126566. PubMed ID: 26176219
[TBL] [Abstract][Full Text] [Related]
24. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
25. The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.
Vallo S; Mani J; Stastny M; Makarević J; Juengel E; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
Invest New Drugs; 2013 Apr; 31(2):265-72. PubMed ID: 22801803
[TBL] [Abstract][Full Text] [Related]
26. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
[TBL] [Abstract][Full Text] [Related]
27. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
[TBL] [Abstract][Full Text] [Related]
28. A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer.
Singel SM; Cornelius C; Batten K; Fasciani G; Wright WE; Lum L; Shay JW
Clin Cancer Res; 2013 Apr; 19(8):2061-70. PubMed ID: 23479679
[TBL] [Abstract][Full Text] [Related]
29. Effective targeting of triple-negative breast cancer cells by PF-4942847, a novel oral inhibitor of Hsp 90.
Mehta PP; Whalen P; Baxi SM; Kung PP; Yamazaki S; Yin MJ
Clin Cancer Res; 2011 Aug; 17(16):5432-42. PubMed ID: 21715568
[TBL] [Abstract][Full Text] [Related]
30. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.
Helland Ø; Popa M; Bischof K; Gjertsen BT; McCormack E; Bjørge L
PLoS One; 2016; 11(6):e0158208. PubMed ID: 27352023
[TBL] [Abstract][Full Text] [Related]
31. Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.
Anbalagan M; Sheng M; Fleischer B; Zhang Y; Gao Y; Hoang V; Matossian M; Burks HE; Burow ME; Collins-Burow BM; Hangauer D; Rowan BG
Mol Cancer Res; 2017 Nov; 15(11):1491-1502. PubMed ID: 28751463
[TBL] [Abstract][Full Text] [Related]
32. Suberoylanilide hydroxamic acid-induced specific epigenetic regulation controls Leptin-induced proliferation of breast cancer cell lines.
Feng X; Han H; Zou D; Zhou J; Zhou W
Oncotarget; 2017 Jan; 8(2):3364-3379. PubMed ID: 27926517
[TBL] [Abstract][Full Text] [Related]
33. Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro.
Chao H; Wang L; Hao J; Ni J; Chang L; Graham PH; Kearsley JH; Li Y
Cancer Lett; 2013 Feb; 329(1):17-26. PubMed ID: 22995071
[TBL] [Abstract][Full Text] [Related]
34. Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer.
Wang G; Niu X; Zhang W; Caldwell JT; Edwards H; Chen W; Taub JW; Zhao L; Ge Y
Cancer Lett; 2015 Jan; 356(2 Pt B):656-68. PubMed ID: 25458954
[TBL] [Abstract][Full Text] [Related]
35. Resveratrol exhibits diverse anti-cancer activities through epigenetic regulation of E-cadherin and p21 in triple-negative breast cancer cells.
Sakamoto T; Tanimoto K; Eguchi H; Sasaki S; Tsuboi K; Hayashi SI; Ichihara S
Breast Cancer; 2023 Sep; 30(5):727-738. PubMed ID: 37166625
[TBL] [Abstract][Full Text] [Related]
36. Effects of Histone Deacetylase Inhibitor Panobinostat (LBH589) on Bone Marrow Mononuclear Cells of Relapsed or Refractory Multiple Myeloma Patients and Its Mechanisms.
Ma Y; Liu W; Zhang L; Jia G
Med Sci Monit; 2017 Oct; 23():5150-5157. PubMed ID: 29080899
[TBL] [Abstract][Full Text] [Related]
37. Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer.
Chan D; Zheng Y; Tyner JW; Chng WJ; Chien WW; Gery S; Leong G; Braunstein GD; Koeffler HP
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1507-14. PubMed ID: 23824064
[TBL] [Abstract][Full Text] [Related]
38. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
[TBL] [Abstract][Full Text] [Related]
39. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo.
Catalano MG; Pugliese M; Gargantini E; Grange C; Bussolati B; Asioli S; Bosco O; Poli R; Compagnone A; Bandino A; Mainini F; Fortunati N; Boccuzzi G
Int J Cancer; 2012 Feb; 130(3):694-704. PubMed ID: 21400508
[TBL] [Abstract][Full Text] [Related]
40. YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer.
Yamanaka K; Nakata M; Kaneko N; Fushiki H; Kita A; Nakahara T; Koutoku H; Sasamata M
Int J Oncol; 2011 Sep; 39(3):569-75. PubMed ID: 21674125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
